Skip to main content
. 2020 Apr 1;10(4):1085–1102.

Figure 3.

Figure 3

The tumor microenvironment under the treatment of immunosuppressants and immune checkpoint inhibitors. Tolerance of donor graft cells is achieved when T cells are inhibited due to immune suppressants, although the risk of tumor recurrence increases. Tumor cell killing can be induced by immune checkpoint therapy, although donor cells will be recognized and killed as well. CNIs: calcineurin inhibitors; MPA: mycophenolic acid; mTORi, mammalian target of rapamycin inhibitors.